Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidiv risiko

• Literatur

• 1 Adam MA, Pura J, Gu L. et al. Extent of surgery for papillary thyroid cancer is not associated with survival. An analysis of 61,775 patients. Ann Surg 2014; 260: 601-607.
• 2 Bartenstein P. Persönliche Mitteilung zum primären Ablationserfolg bei Patienten mit differenziertem Schilddrüsenkarzinom und niedrig-Dosis Radiojodtherapie. Erste Ergebnisse aus der LMU-Kohorte. Nuklearmedizin; 2016
• 3 Brown AP, Chen J, Hitchcock YJ. et al. The risk of second primary malignancies up to three decades after treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93: 504-515.
• 4 Caglar M, Bozkurt FM, Akca CK. et al. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl Med Commun 2012; 33: 268-274.
• 5 Chow SM, Yau S, Kwan CK. et al. Local and regional control in patients with PTC: specific indications of external radiotherapy and radioactive iodine. Endocrine-related Cancer 2006; 13: 1159-1172.
• 6 ClinicalTrials.gov. Identifier: NCT01837745
• 7 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
• 8 Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, Eftekhari M. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun 2012; 33: 275-282.
• 9 Haenscheid H, Lassmann M, Luster M. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47: 648-654.
• 10 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 doi:
• 11 Kukulska A, Krajewska J, Gawkowska-Suwinska M. et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 2010; 3: 9.
• 12 Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomized trial following HiLo. Clin Oncol (R Coll Radiol) 2012; 24: 159-161.
• 13 Mallick U, Harmer C, Yap B. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674-1685.
• 14 Mehanna H, Al-Maqbili T, Carter B. et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21329 person-years of follow-up. J Clin Endocrinol Metab 2014; 99: 2834-2843.
• 15 Oluwasanjo A, Pathak R, Ukaigwe A, Alese O. Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer. Cancer Causes Control 2016; 27: 143-146.
• 16 Orosco RK, Hussain T, Brumund KT. et al. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the surveillance, epidemiology, and end results database. Thyroid 2015; 25: 125-132.
• 17 Park EK, Chung JK, Lim IH. et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009; 36: 172-179.
• 18 Perros P, Colley S, Boelart K. et al. British Thyroid Association guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 2014; 81 (Suppl. 01) 1-122.
• 19 Radivoyevitch T, Sachs RK, Gale RP. et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. 2015 doi:
• 20 Robenshtok E, Grewal RK, Fish S. et al. A low risk postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid 2013; 23: 436-442.
• 21 Rubino C, de Vathaire F, Dottorini ME. et al. Second primary malignancy in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
• 22 Ruel E, Thomas S, Dinan M. et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 2015; 100: 1529-1536.
• 23 Sacks W, Wong RM, Bresee C, Braunstein GD. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid 2015; 25: 377-385.
• 24 Sawka AM, Thephamongkhol K, Brouwers M. et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-3676.
• 25 Schlumberger M, Catargi B, Borget I. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663-1673.
• 26 Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid 2015; 25: 927-934.
• 27 Verburg FA, Mäder U, Reiners C, Hänscheid H. Long-term survival in DTC is worse after low-activity initial post-surgical 131I therapy in both highand low-risk patients. J Clin Endocrinol Metab 2014; 99: 4487-4496.